Newsletter

Subscribe and receive updates on this company

Text STOCKS to 72727 for mobile alerts

We are excited to present AC Immune SA (NASDAQ: ACIU).

Full DD Report for ACIU

You must become a subscriber to view this report.


Recent News from (NASDAQ: ACIU)

Oryzon Genomics commences mid-stage study of Alzheimer's candidate
Spanish biotech Oryzon Genomics announces that enrollment is underway in a Phase 2b clinical trial assessing ORY-2001 in patients with mild-to-moderate Alzheimer's disease (AD). More news on: vTv Therapeutics, Biogen Inc., Tonix Pharmaceuticals Holding Corp., Healthcare stocks news, ...
Source: SeekingAlpha
Date: May, 14 2018 12:27
AC Immune Reports First Quarter 2018 Financial Results and Corporate Update
Announced first-in-human study for an alpha-synuclein PET tracer for Parkinson's disease Selected Tau small molecules (Tau Morphomers) have entered into IND/CTA * enabling studies; Phase 1 to commence by the end of 2018 Increased R&D investment and resources across our key...
Source: GlobeNewswire
Date: May, 02 2018 04:00
AC Immune Announces Results of Extraordinary Shareholders Meeting
Lausanne, Switzerland, April 27, 2018 - AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical stage biopharmaceutical company focused on neurodegenerative diseases, today announced that the shareholders of the Company have approved all resolutions as proposed by the Board of Directors at t...
Source: GlobeNewswire
Date: April, 27 2018 16:31
AC Immune (ACIU) Presents At H. C. Wainwright Global Life Sciences Conference - Slideshow
The following slide deck was published by AC Immune SA in conjunction with this Read more ...
Source: SeekingAlpha
Date: April, 10 2018 12:17
Your Daily Pharma Scoop: Conatus Setback, Applied DNA Signs Agreement, Evolus Announces Results From Late-Stage Study
A nalysis focus: Conatus Conatus (NASDAQ: CNAT ) shares tumbled after the company announced top-line results from a phase 2b POLT-HCV-SVR clinical study. The phase 2b study was evaluating CNAT’s lead product candidate emricasan, a first-in-class pan-caspase protease inhibitor ...
Source: SeekingAlpha
Date: April, 06 2018 11:18
AC immune selects Tau candidates for Alzheimer's disease
AC Immune SA (NASDAQ: ACIU ) announces that several Tau Morphomer candidates have demonstrated target-specific reduction of pathological Tau and cognitive and functional improvement in Alzheimer's disease in preclinical testing. More news on: AC Immune SA, Healthcare stocks news, Rea...
Source: SeekingAlpha
Date: April, 05 2018 08:26
Premarket analyst action - healthcare
AC Immune (NASDAQ: ACIU ) initiated with Buy rating with an $18 (67% upside) price target at H.C. Wainwright. More news on: AC Immune SA, Merck & Co Inc., Pfizer Inc., Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: April, 05 2018 07:21
AC Immune Announces the Selection of Tau Small Molecules for Clinical Development in Alzheimer's disease
Tau small molecules (Tau Morphomers) demonstrate target-specific reduction of pathological Tau as well as cognitive and functional improvement Significant reduction of microglia activation enhances the benefits on Tau pathology Tau Morphomers are capable of crossing the blood b...
Source: GlobeNewswire
Date: April, 05 2018 04:00
Oryzon Genomics on go with mid-stage study of Alzheimer's candidate ORY-2001
Madrid, Spain-based Oryzon Genomics announces that it has received regulatory sign-off for a Phase 2a clinical trial assessing ORY-2001 in patients with mild-to-moderate Alzheimer's disease (AD). More news on: Alzheon, Denali Therapeutics, Inc., Wave Life Sciences, Healthcare stocks news...
Source: SeekingAlpha
Date: April, 04 2018 11:14
Wired News - MediciNova Released Results of Phase-2 Clinical Trial Assessing MN-166 (ibudilast) in Methamphetamine Dependence
Stock Monitor: AC Immune Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 03, 2018 / Active-Investors.com has just released a free research report on MediciNova, Inc. (NASDAQ: MNOV ). If you want access to this report all you need to do is sign up now by clicking the following...
Source: ACCESSWIRE IA
Date: April, 03 2018 07:20

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-189.76610.02410.149.76613,307
2018-05-179.76610.02410.149.76613,307
2017-02-0212.0512.0912.22511.8542,456
2017-02-0112.2011.9812.3011.9847,005
2017-01-3111.8412.0212.3311.800131,609

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-05-218060913.1363Cover
2018-05-183,1013,79281.7774Short
2018-05-172,0825,37838.7133Short
2018-05-164931,01248.7154Short
2018-05-151,8462,77266.5945Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on ACIU.


About AC Immune SA (NASDAQ: ACIU)

Logo for AC Immune SA (NASDAQ: ACIU)

Not available

 

Contact Information

 

 

Current Share Structure

  • Market Cap: $564,948,602 - 05/11/2018
  • Issue and Outstanding: 57,355,188 - 12/31/2017

 


Recent Filings from (NASDAQ: ACIU)

Registration statement for certain foreign private issuers offered for certain transactions
Filing Type: F-3Filing Source: edgar
Filing Date: May, 04 2018
Registration statement for certain foreign private issuers offered for certain transactions
Filing Type: F-3Filing Source: edgar
Filing Date: May, 04 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: May, 02 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: May, 02 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: April, 27 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: April, 27 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: March, 26 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: March, 26 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: March, 22 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: March, 22 2018

 

 


Daily Technical Chart for (NASDAQ: ACIU)

Daily Technical Chart for (NASDAQ: ACIU)


Stay tuned for daily updates and more on (NASDAQ: ACIU)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: ACIU)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

OTC Report
@OTCReporter

 

 


Disclaimer: OTC Report publishes reports providing information on selected companies. OTC Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. OTC Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ACIU is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. OTC Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. OTC Report does not own any shares of ACIU and does not buy, sell, or trade any shares of ACIU. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by OTC Report. All rights reserved. Our Full Disclaimer: http://otc.report/disclaimer/